Search

Your search keyword '"Kwon, Jung-Hyun"' showing total 472 results
Start Over Author "Kwon, Jung-Hyun"
472 results on '"Kwon, Jung-Hyun"'

1. Chemoembolization combined radiofrequency ablation vs. chemoembolization alone for treatment of beyond the Milan criteria viable hepatocellular carcinoma (CERFA): study protocol for a randomized controlled trial

Author

Lee, Soon Kyu, Yang, Hyun, Kwon, Jung Hyun, Shim, Dong Jae, Kim, Doyoung, Nam, Soon Woo, Yoo, Sun Hong, Bae, Si Hyun, Lee, Ahlim, Lee, Young Joon, Jeon, Changho, Jang, Jeong Won, Sung, Pil Soo, Chun, Ho Jong, Kim, Su Ho, Choi, Joon-Il, Oh, Jung Suk, and Yang, Yun-Jung

Published
2023
Full Text
View/download PDF

4. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B

Author

Nam, Heechul, primary, Han, Ji Won, additional, Lee, Soon Kyu, additional, Yang, Hyun, additional, Lee, Hae Lim, additional, Sung, Pil Soo, additional, Song, Myeong Jun, additional, Kwon, Jung Hyun, additional, Jang, Jeong Won, additional, Chang, U‐Im, additional, Kim, Chang Wook, additional, Nam, Soon Woo, additional, Bae, Si Hyun, additional, Choi, Jong Young, additional, Yoon, Seung Kew, additional, Yang, Jin Mo, additional, and Kim, Hee Yeon, additional

Published
2024
Full Text
View/download PDF

5. Expansion of effector regulatory T cells in steroid-responders of severe alcohol-associated hepatitis

Author

Kang, Min Woo, primary, Lee, Soon Kyu, additional, Jang, Eun Ji, additional, Park, Jong Geun, additional, Seo, Deok Hwa, additional, Han, Ji Won, additional, Yoo, Jae Sung, additional, Kwon, Jung Hyun, additional, Nam, Soon Woo, additional, Jang, Jeong Won, additional, Choi, Jong Young, additional, Yoon, Seung Kew, additional, and Sung, Pil Soo, additional

Published
2024
Full Text
View/download PDF

8. Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study.

Author

Nam, Heechul, Lee, Jaejun, Han, Ji Won, Lee, Soon Kyu, Yang, Hyun, Lee, Hae Lim, Sung, Pil Soo, Kim, Hee Yeon, Kim, Seok-Hwan, Song, Myeong Jun, Kwon, Jung-Hyun, Kim, Chang Wook, Nam, Soon Woo, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew, and Jang, Jeong Won

Subjects
DRUG side effects, PORTAL vein, LIVER cancer, HEPATOCELLULAR carcinoma, OVERALL survival
Abstract

Introduction: Despite the emergence of atezolizumab and bevacizumab (A + B) as standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC), a comprehensive understanding of the clinical significance of immune-related adverse events (irAEs) remains limited. We aimed to assess the impact of irAEs on patients with HCC undergoing A + B treatment. Methods: This multicentre retrospective study included consecutive patients with HCC who were treated with the A + B regimen from September 2020 to December 2022. Patients were categorized into three groups based on the severity of irAEs, ranging from those without any experience of irAEs to those with severe irAEs. Results: This study included 150 patients with HCC, with a mean age of 63.3 years. Among them, 93.3% of patients were classified as Barcelona Clinic Liver Cancer stage C, 52.0% had portal vein tumour thrombosis (PVTT), and 60.7% extrahepatic spread. Patients were classified as follows: group 1 (n = 84) had no irAEs, group 2 (n = 37) had mild irAEs (grade 1-2), and group 3 (n = 29) had severe irAEs (grade ≥3). The median overall survival (OS), progression-free survival (PFS), and time-to-treatment discontinuation (TTD) were 13.6, 5.7, and 3.6 months, respectively. Group 2 demonstrated significantly superior OS compared to group 1 (9.5 months) and group 3 (5.6 months), with a median OS of 23.0 months (p < 0.001). Furthermore, group 2 demonstrated significantly better outcomes in terms of PFS and TTD compared to both group 1 and group 3 (p < 0.001 for both). Multivariate analysis identified mild irAEs (hazard ratio [HR], 0.353; p = 0.010), ALBI grade 1 (HR, 0.389; p = 0.006), Child-Pugh class A (HR, 0.338; p = 0.002), and the absence of PVTT (HR, 0.556; p = 0.043) as independent predictors of better OS. Conclusion: Our study highlights the significant impact of irAE severity on the outcomes of patients with HCC receiving A + B. Notably, the occurrence of mild irAEs was independently associated with favourable survival, suggesting their potential role as surrogate indicators of HCC prognosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study

Author

Han, Ji Won, primary, Sung, Pil Soo, additional, Yoo, Jae-Sung, additional, Cho, Hee Sun, additional, Lee, Soon Kyu, additional, Yang, Hyun, additional, Kim, Ji Hoon, additional, Nam, Heechul, additional, Lee, Hae Lim, additional, Kim, Hee Yeon, additional, Lee, Sung Won, additional, Song, Do Seon, additional, Song, Myeong Jun, additional, Kwon, Jung Hyun, additional, Kim, Chang Wook, additional, Bae, Si Hyun, additional, Jang, Jeong Won, additional, Choi, Jong Young, additional, and Yoon, Seung Kew, additional

Published
2024
Full Text
View/download PDF

10. ‘Sweet Queen’ Nectarine

Author

Kwon, Jung Hyun, primary, Nam, Eun Young, additional, Jun, Ji Hae, additional, Chung, Kyeong Ho, additional, Yun, Seok Kyu, additional, Kim, Sung Jong, additional, Lee, Ju-Hyun, additional, Hwang, Kidong, additional, and Jeong, Namhee, additional

Published
2024
Full Text
View/download PDF

11. Environment-Aware and Human-Centric Software Testing Framework for Cyber-Physical Systems

Author

Ko, In-Young, Baek, KyeongDeok, Kwon, Jung-Hyun, Lira, Hernan, Moon, HyeongCehol, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Woeginger, Gerhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Brambilla, Marco, editor, Cappiello, Cinzia, editor, and Ow, Siew Hock, editor

Published
2020
Full Text
View/download PDF

16. Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicenter Cohort Study

Author

Nam, Heechul, primary, Lee, Jaejun, additional, Han, Ji Won, additional, Lee, Soon Kyu, additional, Yang, Hyun, additional, Lee, Hae Lim, additional, Sung, Pil Soo, additional, Kim, Hee Yeon, additional, Kim, Seok-Hwan, additional, Song, Myeong Jun, additional, Kwon, Jung-Hyun, additional, Kim, Chang Wook, additional, Nam, Soon Woo, additional, Bae, Si Hyun, additional, Choi, Jong Young, additional, Yoon, Seung Kew, additional, and Jang, Jeong Won, additional

Published
2023
Full Text
View/download PDF

17. The Clinical Courses and Prognosis of Cirrhotic Patients after First Acute Decompensation: Prospective Cohort Study

Author

Kim, Jung Hee, primary, Kim, Sung-Eun, additional, Song, Do Seon, additional, Kim, Hee Yeon, additional, Yoon, Eileen L., additional, Kang, Seong Hee, additional, Jung, Young-Kul, additional, Kwon, Jung Hyun, additional, Lee, Sung Won, additional, Han, Seul Ki, additional, Chang, Young, additional, Jeong, Soung Won, additional, Yoo, Jeong Ju, additional, Jin, Young-Joo, additional, Cheon, Gab Jin, additional, Kim, Byung Seok, additional, Seo, Yeon Seok, additional, Kim, Hyoungsu, additional, Park, Ji Won, additional, Kim, Tae Hyung, additional, Sinn, Dong Hyun, additional, Chung, Woo Jin, additional, Kim, Hwi Young, additional, Lee, Han Ah, additional, Nam, Seung Woo, additional, Kim, In Hee, additional, Kim, Ji Hoon, additional, Chae, Hee Bok, additional, Sohn, Joo Hyun, additional, Cho, Ju Yeon, additional, Park, Jung Gil, additional, Cho, Hyun Chin, additional, Kim, Yoon Jun, additional, Yang, Jin Mo, additional, Suk, Ki Tae, additional, Kim, Moon Young, additional, Kim, Sang Gyune, additional, Yim, Hyung Joon, additional, Kim, Won, additional, Jang, Jae-Young, additional, and Kim, Dong Joon, additional

Published
2023
Full Text
View/download PDF

22. Long-Term HBsAg Titer Kinetics with Entecavir/Tenofovir: Implications for Predicting Functional Cure and Low Levels.

Author

Lee, Soon Kyu, Nam, Soon Woo, Jang, Jeong Won, and Kwon, Jung Hyun

Subjects
TENOFOVIR, CHRONIC active hepatitis, TITERS
Abstract

The long-term kinetics of quantitative HBsAg levels in HBV-infected patients treated with entecavir or tenofovir, as well as the role of quantitative HBsAg in predicting functional cure (HBsAg loss) and low HBsAg levels (<2 log IU/mL) remain unclear. Of some 1661 consecutively enrolled patients newly treated with entecavir or tenofovir, we analyzed 852 patients who underwent serial HBsAg level checks every 6–12 months. The primary outcomes included long-term kinetics in HBsAg levels and the rate of functional cure and achieving low HBsAg levels. Over a mean 6.3-year follow-up, the functional cure rate was 2.28% (n = 19), and 12.9% (n = 108) achieved low HBsAg levels. A significant HBsAg level reduction was seen in the first treatment year (p < 0.05), with another stepwise decrease between year 6–7. These trends were pronounced in patients with chronic hepatitis and HBeAg-positivity compared to those with cirrhosis and HBeAg-negativity, respectively. Baseline HBsAg of ≤3 log IU/mL and the first-year HBsAg reduction were key predictors for both functional cure and low HBsAg levels (p < 0.05). In conclusion, our findings elucidate the stepwise reduction in quantitative HBsAg dynamics during high-potency NA therapy (entecavir or tenofovir) along with variations based on different conditions. We also underscore the significance of quantitative HBsAg titer in predicting functional cure and low-HBsAg levels. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. The Clinical Courses and Prognosis of Cirrhotic Patients after First Acute Decompensation: Prospective Cohort Study.

Author

Kim, Jung Hee, Kim, Sung-Eun, Song, Do Seon, Kim, Hee Yeon, Yoon, Eileen L., Kang, Seong Hee, Jung, Young-Kul, Kwon, Jung Hyun, Lee, Sung Won, Han, Seul Ki, Chang, Young, Jeong, Soung Won, Yoo, Jeong Ju, Jin, Young-Joo, Cheon, Gab Jin, Kim, Byung Seok, Seo, Yeon Seok, Kim, Hyoungsu, Park, Ji Won, and Kim, Tae Hyung

Subjects
HEPATIC encephalopathy, COHORT analysis, LIVER failure, VIRAL hepatitis, PROGNOSIS, GASTROINTESTINAL hemorrhage, HEPATITIS B
Abstract

Background: The European Foundation for the Study of Chronic Liver Failure (EF-CLIF) consortium suggested that the clinical courses after acute decompensation (AD) stratify the long-term prognosis: stable decompensated cirrhosis (SDC), unstable decompensated cirrhosis (UDC), pre acute-on-chronic liver failure (pre ACLF), and ACLF. However, previous studies included patients with a history of previous AD and had limitations associated with identifying the clinical factors related to prognosis after the first AD. Method: The prospective Korean Acute-on-Chronic Liver Failure (KACLiF) cohort included cirrhotic patients who were hospitalised with first AD between July 2015 and August 2018. We analysed the factors associated with readmission after the first AD and compared the characteristics and prognosis among each subgroup to evaluate the risk factors for the occurrence of pre ACLF after AD. Result: A total of 746 cirrhotic patients who were hospitalised with first AD were enrolled. The subgroups consisted of SDC (n = 565), UDC (n = 29), pre ACLF (n = 28), and ACLF (n = 124). Of note, pre ACLF showed a poorer prognosis than ACLF. The risk factors associated with readmission within 3 months of first AD were non-variceal gastrointestinal (GI) bleeding, hepatic encephalopathy (HE), and high MELD score. Viral aetiology was associated with the occurrence of pre ACLF compared with alcohol aetiology regardless of baseline liver function status. Conclusion: Cirrhotic patients with first AD who present as non-variceal GI bleeding and HE can easily relapse. Interestingly, the occurrence of AD with organ failure within 3 months of first AD (pre ACLF) has worse prognosis compared with the occurrence of organ failure at first AD (ACLF). In particular, cirrhotic patients with viral hepatitis with/without alcohol consumption showed poor prognosis compared to other aetiologies. Therefore, patients with ACLF after AD within 3 months should be treated more carefully and definitive treatment through LT should be considered. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis

Author

Lee, Soon Kyu, primary, Kwon, Jung Hyun, additional, Lee, Sung Won, additional, Lee, Hae Lim, additional, Kim, Hee Yeon, additional, Kim, Chang Wook, additional, Song, Do Seon, additional, Chang, U Im, additional, Yang, Jin Mo, additional, Nam, Soon Woo, additional, Kim, Seok-Hwan, additional, Song, Myeong Jun, additional, Kim, Ji Hoon, additional, Lee, Ahlim, additional, Yang, Hyun, additional, Bae, Si Hyun, additional, Han, Ji Won, additional, Nam, Heechul, additional, Sung, Pil Soo, additional, Jang, Jeong Won, additional, Choi, Jong Young, additional, Yoon, Seung Kew, additional, Shim, Dong Jae, additional, Kim, Doyoung, additional, and Kim, Myungsoo, additional

Published
2023
Full Text
View/download PDF

26. Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study

Author

Heo, Jeong, primary, Kim, Yoon Jun, additional, Lee, Sung Wook, additional, Lee, Youn-Jae, additional, Yoon, Ki Tae, additional, Byun, Kwan Soo, additional, Jung, Yong Jin, additional, Tak, Won Young, additional, Jeong, Sook-Hyang, additional, Kwon, Kyung Min, additional, Suri, Vithika, additional, Wu, Peiwen, additional, Jang, Byoung Kuk, additional, Lee, Byung Seok, additional, Cho, Ju-Yeon, additional, Jang, Jeong Won, additional, Yang, Soo Hyun, additional, Paik, Seung Woon, additional, Kim, Hyung Joon, additional, Kwon, Jung Hyun, additional, Park, Neung Hwa, additional, Kim, Ju Hyun, additional, Kim, In Hee, additional, Ahn, Sang Hoon, additional, and Lim, Young-Suk, additional

Published
2023
Full Text
View/download PDF

28. Efficacy and Safety of Tenofovir Disoproxil Fumarate in Treatment-Naïve Patients with Chronic Hepatitis B in Korea

Author

Kwon, Jung Hyun, Song, Myeong Jun, Jang, Jeong Won, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew, Kim, Hee Yeon, Kim, Chang Wook, Song, Do Seon, Chang, U. Im, Yang, Jin Mo, You, Chan Ran, Choi, Sang Wook, Lee, Hae Lim, Lee, Sung Won, Han, Nam Ik, Nam, Soon Woo, Kim, Sang Gyune, Kim, Young Seok, Kim, Seok Hyun, Lee, Byung Seok, Lee, Tae Hee, and Cho, Eun-Young

Published
2019
Full Text
View/download PDF

31. The prognostic impact of each organ failure is different than that of acute-on-chronic liver failure according to the major clinical presentation in acutely decompensated cirrhosis

Author

Kim, Jung Hee, primary, Kim, Sung-Eun, additional, Song, Do Seon, additional, Jung, Jang Han, additional, Kim, Hyoung Su, additional, Yoon, Eileen, additional, Kim, Tae Hyung, additional, Kwon, Jung Hyun, additional, Jung, Young Kul, additional, Suk, Ki Tae, additional, Kim, Moon Young, additional, kim, sang gyune, additional, Kim, Yoon Jun, additional, Kim, Won, additional, Yang, Jin Mo, additional, Jang, Jae Young, additional, and Kim, Dong Joon, additional

Published
2023
Full Text
View/download PDF

34. Distributed Service Discovery in Mobile IoT Environments Using Hierarchical Bloom Filters

Author

Jo, Hyeon-Jun, Kwon, Jung-Hyun, Ko, In-Young, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, Cimiano, Philipp, editor, Frasincar, Flavius, editor, Houben, Geert-Jan, editor, and Schwabe, Daniel, editor

Published
2015
Full Text
View/download PDF

35. Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study

Author

Yoo, Sun Hong, primary, Kim, Soon Sun, additional, Kim, Sang Gyune, additional, Kwon, Jung Hyun, additional, Lee, Han-Ah, additional, Seo, Yeon Seok, additional, Jung, Young Kul, additional, Yim, Hyung Joon, additional, Song, Do Seon, additional, Kang, Seong Hee, additional, Kim, Moon Young, additional, Ahn, Young-Hwan, additional, Han, Jieun, additional, Kim, Young Seok, additional, Chang, Young, additional, Jeong, Soung Won, additional, Jang, Jae Young, additional, and Yoo, Jeong-Ju, additional

Published
2023
Full Text
View/download PDF

36. Chemoembolization Combined Radiofrequency Ablation vs. Chemoembolization Alone for Treatment of beyond the Milan Criteria viable Hepatocellular Carcinoma (CERFA): Study protocol for a randomized controlled trial

Author

Lee, Soon Kyu, primary, Yang, Hyun, additional, Kwon, Jung Hyun, additional, Shim, Dong Jae, additional, Kim, Doyoung, additional, Nam, Soon Woo, additional, Yoo, Sun Hong, additional, Bae, Si Hyun, additional, Lee, Ahlim, additional, Lee, Young Joon, additional, Jeon, Changho, additional, Jang, Jeong Won, additional, Sung, Pil Soo, additional, Chun, Ho Jong, additional, Kim, Su Ho, additional, Choi, Joon-Il, additional, Oh, Jung Suk, additional, and Yang, Yun-Jung, additional

Published
2023
Full Text
View/download PDF

44. Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study

Author

Lee, Soon Kyu, primary, Lee, Sung Won, additional, Lee, Hae Lim, additional, Kim, Hee Yeon, additional, Kim, Chang Wook, additional, Song, Do Seon, additional, Chang, U Im, additional, Yang, Jin Mo, additional, Yoo, Sun Hong, additional, Kwon, Jung Hyun, additional, Nam, Soon Woo, additional, Kim, Seok-Hwan, additional, Song, Myeong Jun, additional, Lee, Jaejun, additional, Yang, Hyun, additional, Bae, Si Hyun, additional, Han, Ji Won, additional, Nam, Heechul, additional, Sung, Pil Soo, additional, Jang, Jeong Won, additional, Choi, Jong Young, additional, and Yoon, Seung Kew, additional

Published
2022
Full Text
View/download PDF

48. Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease

Author

Ryu, Ji Eun, primary, Song, Myeong Jun, additional, Kim, Seok-Hwan, additional, Kwon, Jung Hyun, additional, Yoo, Sun Hong, additional, Nam, Soon Woo, additional, Nam, Hee Chul, additional, Kim, Hee Yeon, additional, Kim, Chang Wook, additional, Yang, Hyun, additional, Bae, Si Hyun, additional, Song, Do Seon, additional, Chang, U Im, additional, Yang, Jin Mo, additional, Lee, Sung Won, additional, Lee, Hae Lim, additional, Lee, Soon Kyu, additional, Sung, Pil Soo, additional, Jang, Jeong Won, additional, Choi, Jong Young, additional, and Yoon, Seung Kew, additional

Published
2022
Full Text
View/download PDF

49. Efficacy of Liver-Directed Combined Radiotherapy in Locally Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.

Author

Kim, Jina, Cheng, Jason Chia-Hsien, Nam, Taek-Keun, Kim, Jin Hee, Jang, Byoung Kuk, Huang, Wen-Yen, Aikata, Hiroshi, Kim, Myungsoo, Kwon, Jung Hyun, Yue, Jinbo, Lee, Victor Ho Fun, Zeng, Zhaochong, and Seong, Jinsil

Subjects
RESEARCH, THERAPEUTICS, VENOUS thrombosis, TREATMENT effectiveness, CHEMORADIOTHERAPY, CANCER patients, PORTAL vein, SORAFENIB, DESCRIPTIVE statistics, RESEARCH funding, PROGRESSION-free survival, HEPATOCELLULAR carcinoma, OVERALL survival, EVALUATION
Abstract

Simple Summary: In this multinational, multi-institutional study, we investigated the efficacy of liver-directed combined radiotherapy compared with sorafenib in hepatocellular carcinoma patients presenting portal vein tumor thrombosis. Propensity score matching was performed to minimize the imbalance between the two groups. The median overall survival was significantly improved in the LD combined RT group, and the conversion rate to curative surgery was also significantly higher in the LD combined RT group. Despite the multimodality of the treatments, toxicity rates of LD combined RT were comparable to those of sorafenib. Purpose: Although systemic treatment is the mainstay for advanced hepatocellular carcinoma (HCC), numerous studies have highlighted the added value of local treatment. This study aimed to investigate the clinical efficacy of liver-directed combined radiotherapy (LD combined RT) compared with that of sorafenib, a recommended treatment until recently for locally advanced HCC presenting portal vein tumor thrombosis (PVTT), using a multinational patient cohort. Materials and Methods: We identified patients with HCC presenting PVTT treated with either sorafenib or LD combined RT in 10 tertiary hospitals in Asia from 2005 to 2014. Propensity score matching (PSM) was performed to minimize the imbalance between the two groups. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS) and treatment-related toxicity. Results: A total of 1035 patients (675 in the LD combined RT group and 360 in the sorafenib group) were included in this study. After PSM, 305 patients from each group were included in the analysis. At a median follow-up of 22.5 months, the median OS was 10.6 and 4.2 months for the LD combined RT and sorafenib groups, respectively (p < 0.001). The conversion rate to curative surgery was significantly higher (8.5% vs. 1.0%, p < 0.001), while grade ≥ 3 toxicity was fewer (9.2% vs. 16.1%, p < 0.001) in the LD combined RT group. Conclusions: LD combined RT improved survival outcomes with a higher conversion rate to curative surgery in patients with locally advanced HCC presenting PVTT. Although further prospective studies are warranted, active multimodal local treatment involving radiotherapy is suggested for locally advanced HCC presenting PVTT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results